Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against ImmunoCellular Therapeutics, Ltd. (IMUC)

NEW YORK, May 04, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (Nasdaq:IMUC) in the United States District Court for the Central District of California on behalf of purchasers of ImmunoCellular securities from May 1, 2012 through December 11, 2013, inclusive (the “Class Period”).  The lawsuit seeks to recover damages for ImmunoCellular investors under the federal securities laws.

The Complaint alleges that that Defendants made false and misleading statements and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote ImmunoCellular, which led the market to believe that ImmunoCellular’s clinical studies for its product candidate ICT-107 was going well.  As a result of this scheme, ImmunoCellular’s share price was artificially inflated.  On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against ImmunoCellular, as well as other individuals and entities, for engaging in stock promotion schemes

If you wish to serve as lead plaintiff, you must move the Court no later than June 30, 2017.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].

Please visit our website at http://www.gme-law.com for more information about the firm.